2017 imagine - abbvie · pdf fileimagine 2017 a company that takes on the toughest health...

IMAGINE2017

A COMPANY THAT TAKES ON THE TOUGHEST HEALTH CHALLENGES

BUT DOES MUCH MORE THAN JUST TREAT DISEASES

PEOPLE. PASSION. POSSIBILITIES.®

~29,000EMPLOYEES GLOBALLY

175+ COUNTRIES WHERE OUR PRODUCTS ARE SOLD

13MANUFACTURING FACILITIES

8R&D RESEARCH CENTERS

2 | ABBVIE ABBVIE | 3

FOCUS MATTERSWe focus on discovering, developing, and delivering drugs in therapeutic areas where we have proven expertise and where we can have an impact. These areas include:

• IMMUNOLOGY

• ONCOLOGY

• VIROLOGY

• NEUROSCIENCE

Images

Top: Employees in 50 countries volunteer during AbbVie’s annual Week of Possibilities.

Far left: In the Philippines, we support Direct Relief’s health clinics.

Far right: Select global awards and recognition.

From FORTUNE Magazine, March 1, 2017 ©2017 Time Inc. FORTUNE and The World’s Most Admired Companies are registered trademarks of Time Inc. and are used under license. FORTUNE and Time Inc. are not affiliated with, and do not endorse products or services of, AbbVie.

It takes a global leader to deliver patient-centered solutions around the world. We uniquely combine the assets and capabilities of an experienced pharmaceutical company with the flexibility and focus of a biotech to pursue the most meaningful opportunities for patients. The result is a research-driven biopharmaceutical company committed to developing innovative advanced therapies to address today’s health issues — from life-threatening illness to chronic conditions.

We target specific difficult-to-cure diseases where we can leverage our core research and development (R&D) expertise to advance science and create solutions that go beyond treating the illness to have a positive impact on patients’ lives, as well as on economies, societies, and science itself. We look at problems holistically, from many perspectives, because that’s how you find the best solutions to the world’s increasingly complex challenges.

WE ARE ABBVIE, A HIGHLY FOCUSED, RESEARCH-DRIVEN BIOPHARMACEUTICAL COMPANY.

Contains 2016 Data

ABBVIE HELPS PATIENTS THROUGHOUT THEIR JOURNEY

81PROGRAMS IN THE U.S.

260PROGRAMS GLOBALLY

PATIENT SUPPORT PROGRAMS

175+COUNTRIES WHERE OUR PRODUCTS HELP PATIENTS

32 CONDITIONS TREATED ACROSS INFANT, ADOLESCENT, ADULT, AND SENIOR STAGES OF LIFE

ABBVIE IS COMMITTED TO HELPING PATIENTS

UNDERSTANDING THE PATIENT EXPERIENCE

ABBVIE IS COMMITTED TO UNDERSTANDING THE PATIENT EXPERIENCE ACROSS COUNTRIES AND CONDITIONS TO REDUCE BARRIERS TO TREATMENT AND AVOIDABLE HEALTHCARE SPENDING

NEARLY

79,000 U.S. PATIENTS RECEIVED MEDICINE AT NO COST

ACCESS TO MEDICINEAbbVie supports patient assistance programs to help qualified people access their needed AbbVie medicine at no cost.

IMPROVING HEALTH OUTCOMESAcross Europe, our Sustainable Healthcare initiative convenes academia, healthcare providers, patient groups, and industry stakeholders. It develops projects and provides, through pilots, evidence and long-term solutions to inform policy, improve efficiency and use of public resources, and care delivery. Learn more at abbvie.com/sustainable-healthcare.com.

ACROSS 21 EUROPEAN COUNTRIES

1 million+PATIENTS REACHED THROUGH INNOVATIVE MEDICAL EDUCATION PROGRAMS

30 pilotsMORE THAN


IMPACT ON PATIENTS

In Kosovo, healthcare workers with a premature baby.

28+ MILLIONPATIENTS TREATED BY ABBVIE’S MEDICINES IN 2016 GLOBALLY

3 MILLION+PATIENT IMPACTS THROUGH ABBVIE PATIENT SUPPORT PROGRAMS GLOBALLY

2 MILLIONPATIENT IMPACTS THROUGH SUPPORT PROGRAMS IN THE U.S.

PROACTIVELY SUPPORTING PATIENTS THROUGH ABBVIE PROGRAMS

PUTTING THE PATIENT AT THE CENTER—PARTNERING TO SUPPORT NEONATOLOGY GLOBALLY

AbbVie’s Good to Grow initiative is supporting premature babies in more than 20 countries. It aims to improve the standards of prevention, care, and support for premature infants and the consequences associated with prematurity. With stakeholders, the initiative is shaping local healthcare systems to deliver the best possible services and care for every premature infant.

WORLDWIDE,

15 MILLION BABIES ARE BORN PRE-TERM1

GOOD TO GROW EFFORTS:

CONVENED GLOBAL SUMMITS ON PREMATURITY WITH 26 COUNTRIES FROM 5 CONTINENTS REPRESENTED

20+ COUNTRIES WITH COALITIONS TO ENSURE EVERY PREMATURE BABY HAS THE HIGHEST QUALITY HEALTHCARE

Contains 2016 DataContains 2016 Data

200+ ONCOLOGY CLINICAL TRIALS

16 POTENTIAL NEW MEDICINES OR NEW INDICATIONS FOR EXISTING MEDICINES IN ONCOLOGY CLINICAL TRIALS

89,500+ PATIENTS GLOBALLY

35,000+ PATIENTS IN THE U.S.

PARTICIPATING IN CLINICAL TRIALS

ABBVIE HAS A ROBUST PIPELINE

OF PHASE 3/3B PIPELINE PROGRAMS ARE CONSIDERED A “NOVEL MECHANISM OF ACTION,” WHICH IS CONSIDERED “FIRST-IN-KIND” IN THE SCIENTIFIC COMMUNITY

67%

MULTIPLE NEW MOLECULES ARE BEING STUDIED IN MORE THAN 20+ CANCERS AND TUMOR TYPES

82+ MILLION POTENTIAL PATIENTS

LIVE IN THE U.S.

OUR TALENTED EMPLOYEESINVESTMENT

8,000+ WORKING IN SCIENCE GLOBALLY

5,200+ WORKING IN SCIENCE IN THE U.S.

1/10 ABBVIE EMPLOYEES

1/25WORKERS IN THE U.S.3

HAVE A DOCTORAL DEGREE

21 STATE-OF-THE-ART R&D AND MANUFACTURING CENTERS

ABBVIE HAS

50+ ACTIVE CLINICAL DEVELOPMENT PROGRAMS

GLOBALLY THERE IS POTENTIAL TO TREAT APPROXIMATELY

400 MILLION

PEOPLE LIVING WITH CONDITIONS ABBVIE’S PIPELINE AIMS TO TREAT

ABBVIE ADVANCES SCIENCE THROUGH…

NEW MOLECULAR ENTITIES (NMEs)

OF R&D DOLLARS ARE INVESTED IN THE U.S.

3 NME INDICATIONS ADVANCED TO PHASE 3

2 NME INDICATIONS ADVANCED TO PHASE 2 WITH REGISTRATION POTENTIAL

5 KEY PROGRAM REGISTRATION SUBMISSIONS

13 KEY PROGRAM REGULATORY APPROVALS

vs

ADJUSTED R&D SPEND

$4.2 BILLION

ADVANCING SCIENTIFIC KNOWLEDGE EVERY DAY Our scientists in the medical research community published more than 940 papers in 2016—allowing others to build on scientific knowledge we developed.

We’re also constantly looking for great ideas outside our own walls. More information is available at www.openinnovation.abbvie.com.

DRIVING INNOVATION, TOGETHER AbbVie partners with approximately 310 leading biotechs, universities, nonprofits, and government organizations to collaborate and advance science every year.The acquisition of Stemcentrx and its unique cancer stem cell approach provides us with a potential way to target the root cells of tumors. These cells are responsible for helping tumors to reproduce and spread throughout the body. The Stemcentrx discovery and early development platform, combined with AbbVie’s ongoing discovery efforts in oncology, create a powerful engine to produce a steady stream of new novel targets and medicines in solid tumors.

Consistent with our long-term strategy and large investment in R&D, we have a number of programs in mid- and late-stage development and continue to make significant pipeline advancements.

77%

57 COUNTRIES WITH CLINICAL TRIALS


IMPACT ON SCIENCE

8,000+ R&D EMPLOYEES AT WORK TODAY AbbVie’s innovation is driven by leading scientists and facilities. IDEA Pharma’s Productive Innovation Index ranked AbbVie number 5 among the top 30 pharmaceutical companies most successful at developing and commercializing new medicines.2

INVESTING $4.2 BILLION TO ADVANCE SCIENCE It takes unwavering commitment and confidence to bring solutions from the petri dish to patients. AbbVie invested $4.2 billion* in research and development (R&D) in 2016 to discover and test compounds with the potential to treat more than 400 million people across the globe. AbbVie is deeply committed to efforts that advance science and solve the world’s toughest health challenges.

*Reflects 2016 R&D investment excluding specified items. 2016 GAAP R&D investment totaled $4.4B.


23,000+ COMPOUNDS PROVIDED FOR SCREENING AGAINST NTDs

9,500+ SAFETY ASSAYS PERFORMED ON COMPOUNDS

70 countriesRECEIVED PRODUCT DONATIONS AND GRANTS FROM ABBVIE AND THE ABBVIE FOUNDATION IN RESPONSE TO NATURAL AND HUMANITARIAN DISASTERS

450+MEDICAL MISSIONS BY PARTNERS AMERICARES, HEART TO HEART INTERNATIONAL, MAP INTERNATIONAL, AND PROJECT HOPE

2015 TO 2016 INCREASE IN RECYCLING RATE FOR HAZARDOUS AND NON-HAZARDOUS WASTE

37%

50 countriesPARTICIPATED IN WEEK OF POSSIBILITIES

26,000+EMPLOYEE VOLUNTEER HOURS IN A SINGLE WEEK

ABBVIE PROTECTS THE ENVIRONMENT

ABBVIE IS COMMITTED TO ENVIRONMENTAL STEWARDSHIP

20%

OF THE WORLD’S POPULATION SUFFERS FROM NEGLECTED TROPICAL DISEASES (NTDs)4

NEARLY 250ABBVIE SCIENTISTS VOLUNTEERED TIME TO FIND SOLUTIONS

21,580+HOURS OF EXPERTISE TO HELP SOLVE NTDs

ABBVIE VOLUNTEERS EXPERTISE TO COMBAT NEGLECTED DISEASES

ABBVIE’S SIGNATURE VOLUNTEER INITIATIVE: WEEK OF POSSIBILITIES

FROM 2013 TO 2016, ABBVIE REDUCED ITS ABSOLUTE CARBON DIOXIDE EQUIVALENT EMISSIONS BY

METRIC TONS58 million

6,000+EMPLOYEE VOLUNTEERS

THESE REDUCTIONS EQUATE TO REMOVING 12 MILLION CARS FROM THE ROAD5


THE ABBVIE FOUNDATIONThe AbbVie Foundation is a nonprofit 501(c)(3) entity. It is dedicated to having a remarkable impact on the lives of the underserved around the world through a commitment to building strong communities, sustainable healthcare systems, and effective educational programs. INVESTING IN TOUGH HEALTH CHALLENGES

An estimated one billion people suffer from neglected tropical diseases.4 In response, nearly 250 of AbbVie’s most experienced scientists voluntarily contribute expertise to partner organizations and help advance the discovery and development of new medicines for onchocerciasis (river blindness), lymphatic filariasis (elephantiasis), malaria, and tuberculosis. Since 2013, AbbVie scientists have dedicated 60,000 pro bono hours to researching neglected diseases.

We collaborate with partners to narrow the achievement gap in

science and literacy.

IMPACT ON SOCIETIES


56,000SUPPLIERS GLOBALLY

$8 BILLION+SPENT WITH THIRD PARTIES GLOBALLY

$6 BILLION+SPENT WITH THIRD PARTIES IN THE U.S.

13 MANUFACTURING FACILITIES

156 countries

SUPPLIERS IN

50 states

8 R&DRESEARCH CENTERS

ABBVIE HAS A PRESENCE IN ALL 50 STATES

1,300+EMPLOYEES IN CALIFORNIA

~9,000EMPLOYEES IN ILLINOIS

SUPPLIERS IN


ABBVIE HAS A LARGE PRESENCE AROUND THE WORLD

EACH JOB AT ABBVIE CREATES OPPORTUNITY FOR OTHERS AbbVie is an economic multiplier. With approximately 29,000 employees globally, our total impact on employment is up to four times that amount through direct and indirect business activity.6 The jobs we create pay well and attract a workforce with diverse skills and educations, including Ph.D. research scientists, laboratory technicians, support staff and more, who live, work, and spend money in their local communities. We also spend millions of dollars each year with suppliers purchasing goods and services. This all provides benefits for third-party suppliers and local economies in the form of higher sales, tax revenue, and economic development.We value the diverse backgrounds and perspectives of our employees, and we have an inclusive culture. AbbVie is also committed to recruit, engage, and support U.S. troops and veterans as they re-enter civilian life.

56,000 SUPPLIERS BENEFIT FROM OUR $8 BILLION IN SPENDING In 2016, AbbVie spent more than $8 billion with more than 56,000 third-party suppliers across multiple industries. AbbVie creates opportunities and growth in industries that support the discovery, development, and distribution of new medicines. This investment includes diverse suppliers: AbbVie spent over $515 million with approximately 2,000 U.S. small and diverse-owned businesses in 2016.

ABBVIE CREATES JOBS & STIMULATES ECONOMIC ACTIVITY

IMPACT ON ECONOMIES

~900EMPLOYEES IN MASSACHUSETTS

TOTAL R&D AND MANUFACTURING LOCATIONS

ILLINOIS HOUSES OUR LARGEST EMPLOYEE BASE GLOBALLY

References 1. World Health Organization. Preterm birth fact sheet. http://www.

who.int/mediacentre/factsheets/fs363/en. Reviewed November 2016. Accessed March 24, 2017.

2. IDEA Pharma. Productive innovation index 2016 white paper. http://ideapharma.com/uploads/white-papers/Productive-Innovation-Index-2016-White-Paper.pdf. Accessed March 24, 2017.

3. Bureau of Labor Statistics. Educational attainment for workers 25 years and older by detailed occupation. https://www.bls.gov/emp/ep_table_111.htm. Published November 4, 2016. Accessed March 24, 2017.

4. Centers for Disease Control and Prevention. Neglected tropical diseases. http://www.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdf. Accessed March 24, 2017.

5. United States Environmental Protection Agency Greenhouse Gas Equivalencies Calculator. https://www.epa.gov/energy/greenhouse-gas-equivalencies-calculator. Accessed April 12, 2017.

6. 2016 PhRMA Profile Report. http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-profile.pdf. Accessed March 24, 2017.

abbvie.com abbvie.com/responsibility

Contains 2016 Data

2017 imagine - abbvie · pdf fileimagine 2017 a company that takes on the toughest health...

Documents